Delivery is the only definitive treatment for hypertensive disorders of pregnancy, but when and how it happens depends on the type of disorder, its severity, and how far along the pregnancy is. For most people with gestational hypertension or preeclampsia without severe features, guidelines worldwide recommend delivery at or shortly after 37 weeks. For severe preeclampsia, the threshold can be much earlier, sometimes before 34 weeks if the mother’s condition deteriorates rapidly. The challenge in every case is the same: delivering sooner protects the mother, but delivering too early exposes the baby to the risks of prematurity. How clinicians navigate that trade-off has shifted meaningfully in the past decade, shaped by several large trials.
Why Delivery Is the Treatment
Hypertensive disorders of pregnancy, including gestational hypertension, preeclampsia, chronic hypertension with superimposed preeclampsia, and eclampsia, all share one thing in common: the placenta is at the center of the problem. In preeclampsia specifically, abnormal placental development triggers a cascade of inflammation and blood vessel damage that affects the mother’s kidneys, liver, brain, and cardiovascular system. Medications can manage blood pressure and prevent seizures, but they cannot fix the underlying placental dysfunction. Removing the placenta by delivering the baby is what resolves the disease process, though some complications can still emerge or worsen in the days after delivery.
That biological reality is why every major clinical practice guideline frames the conversation around timing of delivery rather than alternative treatments. A systematic review of international guidelines found that all of them recommended delivery at term for preeclampsia, and most recommended it even earlier when the disease was classified as severe.
Delivery Timing at Term
For people who reach 37 weeks or beyond with gestational hypertension or preeclampsia without severe features, the evidence strongly favors induction of labor rather than waiting. A Cochrane systematic review pooling data from six trials and over 3,400 participants found that planned early delivery cut the risk of maternal death and severe complications by roughly half compared with expectant management, with no increase in cesarean delivery rates.
The same review found that planned early delivery likely reduced stillbirth substantially, while rates of neonatal unit admission were similar between the two groups.
The more recent WILL trial, a randomized study of women with chronic or gestational hypertension who reached term, tested induction at around 38 and a half weeks versus waiting. Births in the intervention group happened about six days earlier on average. The trial found no meaningful difference in poor maternal outcomes, no difference in neonatal intensive care admissions, and no increase in cesarean rates.
Taken together, these findings explain why guidelines from organizations like ACOG, NICE, the WHO, and SOGC all converge on recommending delivery at term for gestational hypertension and preeclampsia.
The Late Preterm Window, 34 to 37 Weeks
The decision gets harder between 34 and 37 weeks, because babies born in this window still face meaningful risks from prematurity, especially breathing problems. The PHOENIX trial, a large randomized study of people with late preterm preeclampsia, is the key piece of evidence here. It found that planned delivery in this window reduced a composite of serious maternal outcomes: roughly two-thirds of women in the planned delivery group experienced the maternal endpoint compared with three-quarters in the expectant management group.
But the trade-off showed up clearly on the neonatal side. Neonatal unit admissions were higher in the planned delivery group, though the researchers noted that indicators of actual neonatal illness were similar between groups. In other words, more babies were admitted to the neonatal unit, largely because of prematurity-related policies, but they were not sicker in ways that mattered long-term. The trial’s authors concluded that this trade-off should be discussed openly with patients to support shared decision-making.
An individual participant data meta-analysis looking at planned delivery from 34 weeks onward confirmed the pattern: maternal complications dropped from about 4.4% to 2.6% with planned delivery, but short-term neonatal respiratory problems ticked upward. Babies in the expectant management group, meanwhile, were more likely to be born small for gestational age, reflecting the toll that ongoing preeclampsia can take on fetal growth.
Early Preterm Preeclampsia, Before 34 Weeks
When severe preeclampsia develops before 34 weeks, the stakes on both sides escalate. The baby faces serious prematurity risks, but the mother faces life-threatening complications including HELLP syndrome (a dangerous breakdown of red blood cells and liver function), placental abruption, kidney failure, and stroke.
Most guidelines recommend expectant management between viability and about 34 weeks when conditions allow, meaning the mother stays in the hospital under close surveillance, receiving medications to control blood pressure and corticosteroids to accelerate the baby’s lung development. A landmark trial comparing aggressive delivery versus expectant management between 28 and 32 weeks found that expectant management allowed pregnancies to continue an average of two additional weeks. Babies in the expectant group had higher birth weights, lower rates of neonatal intensive care admission, fewer days in the hospital, and fewer complications.
But expectant management has limits. One study of severe preterm preeclampsia with intrauterine growth restriction found that these pregnancies may not benefit from waiting beyond the 48 hours needed for corticosteroids to take effect, because the fetal condition can deteriorate quickly. Research into early-onset severe preeclampsia diagnosed before about 25 and a half weeks suggests that the chances of a good neonatal outcome drop sharply at very early gestational ages, and some investigators have questioned whether expectant management is worthwhile before that threshold.
The practical upshot: between viability and 34 weeks, the goal is to buy time for the baby while watching the mother closely. The moment the mother develops uncontrollable blood pressure, signs of organ damage, or the fetal monitoring becomes worrisome, delivery happens regardless of gestational age.
Fetal Surveillance and When the Baby Decides the Timeline
Even when the mother’s condition seems stable, the baby’s condition can force an earlier delivery. Umbilical artery Doppler ultrasound, which measures blood flow through the cord, is one of the key surveillance tools. A study of women with severe preeclampsia found that abnormal Doppler results were associated with nearly a fourfold increase in the odds of needing delivery before 34 weeks. When blood flow was severely compromised, with absent end-diastolic flow in the umbilical artery, the likelihood of delivering before 34 weeks and undergoing a primary cesarean both jumped significantly. Neonatal complications, including respiratory distress syndrome, were also much more common when Doppler results were abnormal.
This is why expectant management is not simply watching and waiting. It involves frequent, sometimes daily, fetal monitoring. Deteriorating Doppler findings, abnormal fetal heart rate tracings, or signs of growth restriction can all trigger the decision to deliver even if the mother’s blood pressure numbers look acceptable.
Vaginal Birth Versus Cesarean
A common assumption is that hypertensive disorders automatically mean a cesarean delivery, but the evidence does not support that. Induction of labor is appropriate in many cases, and the success rates are better than many people expect. A large study of over 18,000 women who were induced for preeclampsia found that about 71% delivered vaginally. Even at preterm gestational ages between 23 and 36 weeks, about two-thirds achieved a vaginal delivery. The strongest predictors of successful vaginal birth were having had a prior vaginal delivery and younger maternal age.
At very early gestational ages, success rates are lower. A study of early-onset severe preeclampsia found that among women induced between 24 and 28 weeks, only about 7% delivered vaginally. Between 28 and 32 weeks, that figure rose to roughly half, and between 32 and 34 weeks it reached about 69%. The study found that induction of labor at these gestational ages was not associated with increased neonatal illness or death after accounting for gestational age and other factors.
The decision between induction and planned cesarean depends on factors like gestational age, cervical readiness, fetal presentation, and how urgently the baby needs to be delivered. In truly emergent situations, such as eclamptic seizures, severe fetal distress, or placental abruption, cesarean delivery is often the fastest and safest route.
Blood Pressure Control During and Around Delivery
Acute severe hypertension during labor and delivery is dangerous. Blood pressures above 160/110 mmHg significantly raise the risk of stroke and other catastrophic events. The two most commonly used medications are intravenous labetalol and oral nifedipine, and research consistently shows that both work well.
A large randomized trial comparing nifedipine, labetalol, and methyldopa for severe hypertension in pregnancy found that nifedipine achieved blood pressure control within six hours significantly more often than methyldopa, while the difference between nifedipine and labetalol was not quite statistically significant. Smaller trials have found that nifedipine may work somewhat faster, with one study reporting a mean time to target blood pressure of about 27 minutes for nifedipine versus 37 minutes for labetalol. Both drugs required crossover treatment in about one in five patients in another trial, and the overall blood pressure trajectories were similar.
The practical advantage of oral nifedipine is that it does not require an IV line, which can be useful in resource-limited settings or when rapid treatment is needed before vascular access is established. Many protocols use both medications in sequence, starting with one and switching to the other if the first does not bring the pressure down adequately.
Magnesium Sulfate for Seizure Prevention
Magnesium sulfate is the standard treatment for preventing eclamptic seizures in women with preeclampsia, especially when features are severe. The typical protocol involves a loading dose given intravenously over 15 to 20 minutes, followed by a continuous infusion that traditionally runs for 24 hours after delivery or after the last seizure.
That 24-hour postpartum duration has been questioned by recent research. A systematic review and meta-analysis of randomized trials comparing shortened magnesium sulfate courses to the traditional 24-hour regimen found no difference in eclampsia rates or total complication rates between the two approaches. The shortened course did result in less flushing, a common and uncomfortable side effect. Shorter courses also mean less time tethered to an IV pole, which matters for new parents trying to bond with their babies. Some hospitals have begun adopting 12-hour postpartum protocols based on this evidence, though the traditional 24-hour course remains widely used.
Anesthesia Considerations
Anesthesia for someone with preeclampsia is not straightforward. General anesthesia carries the risk of a dangerous blood pressure spike during intubation. Regional anesthesia, whether spinal or epidural, can cause a drop in blood pressure, which is normally managed with IV fluids, but aggressive fluid loading in preeclampsia risks pulmonary edema.
A randomized trial comparing general, epidural, and spinal anesthesia for cesarean delivery in severe preeclampsia found that all three methods were acceptable when managed carefully. Regional anesthesia-related drops in blood pressure were managed without excessive fluid administration, and general anesthesia-related blood pressure spikes were controlled without severe hypertensive complications. A separate study specifically looking at low-dose spinal anesthesia in preeclamptic women confirmed that the risk of dangerous hypotension was lower than previously feared, and that spinal anesthesia could be safely used for cesarean delivery in severe cases.
The key message is that preeclampsia does not automatically rule out any anesthetic technique, but it does require the anesthesiologist to be prepared for the particular hemodynamic challenges the condition creates. Early epidural placement during labor is often encouraged so that it is already in place if an urgent cesarean becomes necessary, avoiding the risks of emergency general anesthesia.
Postpartum Blood Pressure Monitoring
Many people are surprised to learn that preeclampsia does not end the moment the baby is born. Blood pressure often rises in the first few days after delivery, typically peaking between days three and seven. A large cohort study found that over 80% of individuals with hypertensive disorders of pregnancy had persistent hypertension after hospital discharge, and about 14% had severe hypertension after going home. A study comparing postpartum blood pressure in women with severe preeclampsia versus normotensive women found daily systolic and diastolic increases of about 5.6 and 4.6 mmHg, respectively, in the preeclampsia group during the first three days after delivery, compared with minimal changes in the normotensive group.
This postpartum rise is why many hospitals now schedule follow-up blood pressure checks within a week of discharge, and why patients are advised to seek emergency care if they experience headaches, vision changes, or upper abdominal pain after going home. Eclampsia can occur for the first time in the postpartum period, making vigilance critical even after a seemingly smooth delivery.
Neonatal Outcomes by Gestational Age
The baby’s prognosis depends heavily on gestational age at delivery. A study examining neonatal outcomes by week found that babies born at 35 and 36 weeks to mothers with hypertensive disorders had substantially higher rates of being small for gestational age and of neonatal intensive care admission compared with babies born at the same ages to mothers without hypertension. At 35 weeks, small-for-gestational-age rates were roughly 18% in hypertensive pregnancies versus under 2% in normotensive ones. Even at 37 weeks, neonatal unit admissions and length of hospital stay were higher in the hypertensive group, with these differences driven largely by cases requiring labor induction.
This does not mean that earlier delivery is always worse for the baby. In the expectant management window before 34 weeks, delaying delivery allows the baby to grow and mature, but it also means the baby remains in an environment of compromised placental blood flow. Babies born after prolonged expectant management can be growth-restricted and at risk of hypoxic injury. The trade-off is genuinely case by case.
HELLP Syndrome and Severe Complications
HELLP syndrome, a severe form of preeclampsia involving hemolysis, elevated liver enzymes, and low platelets, represents one of the most dangerous scenarios. In a study of 442 pregnancies complicated by HELLP, maternal mortality was about 1%, and serious complications included disseminated intravascular coagulation in 21% of cases, placental abruption in 16%, acute renal failure in about 8%, and pulmonary edema in 6%.
Placental abruption, in which the placenta separates from the uterine wall before delivery, is a particularly feared complication. It can occur even when blood pressures are not markedly elevated. A case report described a patient whose initial blood pressure was 130/85 mmHg but who developed fetal bradycardia and emergency surgery revealed complete abruption with previously undiagnosed preeclampsia. Epidemiologically, experiencing a preterm abruption more than doubles the risk of preeclampsia in a future pregnancy.
Long-Term Cardiovascular Risk After HDP
The consequences of hypertensive disorders of pregnancy extend well beyond the postpartum period. Women who have had preeclampsia face a significantly higher lifetime risk of chronic hypertension, heart disease, stroke, and heart failure. A claims-based study found that a single episode of preeclampsia raised the risk of a subsequent cardiovascular event by about 29% and the risk of chronic hypertension by more than fourfold. For women with recurrent preeclampsia, the cardiovascular risk climbed to about 53% higher, and the hypertension risk was sixfold. Many develop chronic hypertension within a decade of their affected pregnancy.
The underlying mechanisms appear to include lasting changes to blood vessel function, structural changes to the heart such as left ventricular thickening and impaired relaxation, and accelerated coronary artery calcification. These are not just laboratory findings. They translate into higher rates of heart attacks, strokes, and heart failure with preserved ejection fraction in the decades that follow.
This has prompted growing calls for women with a history of preeclampsia to be treated as a cardiovascular risk group, with regular blood pressure monitoring, lipid screening, and lifestyle counseling starting well before the age when cardiovascular disease typically manifests.
Racial Disparities in HDP Outcomes
In the United States, Black women bear a disproportionate burden of hypertensive disorders of pregnancy and their complications. A national analysis of preeclampsia hospitalizations from 2004 to 2019 found that Black, Hispanic, and Asian/Pacific Islander women with preeclampsia had higher in-hospital mortality compared with White women across all income levels. Strikingly, high-income Black women had higher odds of peripartum cardiomyopathy, stroke, acute kidney injury, heart failure, and cardiac arrhythmia than low-income White women, suggesting that income alone does not explain the gap.
A separate study found that African American women with preeclampsia or eclampsia had nearly three times the unadjusted odds of in-hospital death compared with White women, and after adjusting for other health conditions, the risk remained nearly threefold. The Preeclampsia Foundation formed a national task force specifically to address racial disparities in HDP, identifying the need for better quality metrics in obstetrical care and more research into why these gaps persist.
Biomarkers That May Refine Delivery Timing
One of the frustrations in managing preeclampsia is that the clinical picture can change rapidly and unpredictably. Blood pressure readings and urine protein levels tell you what is happening now but are not great at predicting what will happen next week. Researchers have been investigating blood-based biomarkers that could improve prediction.
The most studied is the ratio of two proteins called sFlt-1 and PlGF, which reflect the degree of placental vascular dysfunction. A large validation study published in the New England Journal of Medicine found that when the ratio was low (38 or below), it was extremely good at ruling out preeclampsia in the following week, with a negative predictive value over 99%. The positive predictive value was lower: a high ratio meant about a one-in-three chance of developing preeclampsia within four weeks. This makes the test much better at telling you who is safe to wait than at telling you who needs delivery immediately.
Subsequent research has suggested the ratio could help identify which high-risk patients need the closest monitoring and which need corticosteroids for fetal lung maturation, but studies have concluded that its role in directly planning the date of delivery still needs further investigation in prospective trials.
Emotional Aftermath for Parents
The clinical conversation about HDP delivery tends to focus on physical outcomes, but the psychological toll can be significant. Qualitative research with mothers who experienced preeclampsia has found that many suffer from lasting emotional trauma, including depression, self-blame about their baby’s health, fear of recurrence in future pregnancies, and disrupted bonding with their newborn. These effects are amplified when the baby requires neonatal intensive care, which happens frequently in preterm deliveries for HDP. Healthcare teams and families often underestimate the mental health needs of these mothers, leaving gaps in postpartum support that can persist for years.
HDP Delivery in Low-Resource Settings
Most of the large trials guiding delivery timing for HDP were conducted in well-resourced hospitals with round-the-clock neonatal intensive care. In low- and middle-income countries, where hypertensive disorders of pregnancy cause a higher proportion of maternal deaths, the calculus is different. The neonatal risks of early delivery are greater when high-level neonatal care is unavailable, but the maternal risks of waiting are also greater because complications may not be caught or managed as quickly. A trial protocol designed for these settings acknowledged that the balance of risks needs careful reassessment before applying high-income-country recommendations, particularly because the threshold at which early delivery’s benefits outweigh its harms may shift when neonatal support infrastructure is limited.
Oral nifedipine’s effectiveness as a first-line blood pressure treatment has particular relevance here, since it does not require intravenous access, cold-chain storage, or infusion pumps. The ability to manage acute severe hypertension with a tablet rather than an IV drip can be the difference between timely treatment and dangerous delay in facilities without reliable equipment or staffing.